EP0871641A1 - Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) - Google Patents

Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)

Info

Publication number
EP0871641A1
EP0871641A1 EP95917696A EP95917696A EP0871641A1 EP 0871641 A1 EP0871641 A1 EP 0871641A1 EP 95917696 A EP95917696 A EP 95917696A EP 95917696 A EP95917696 A EP 95917696A EP 0871641 A1 EP0871641 A1 EP 0871641A1
Authority
EP
European Patent Office
Prior art keywords
antibody
tnf
human
chimeric
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95917696A
Other languages
German (de)
English (en)
Other versions
EP0871641A4 (fr
Inventor
Marc Feldmann
Ravinder Nath Maini
James N. Woody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Janssen Biotech Inc
Original Assignee
Kennedy Institute of Rheumotology
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology, Centocor Inc filed Critical Kennedy Institute of Rheumotology
Publication of EP0871641A1 publication Critical patent/EP0871641A1/fr
Publication of EP0871641A4 publication Critical patent/EP0871641A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

L'invention concerne un procédé pour traiter un individu souffrant d'une maladie liée au facteur nécrosant des tumeurs, consistant à administrer à cet individu des doses multiples d'anticorps anti-TNF, où la seconde dose ou les doses subséquentes sont administrées pendant ou immédiatement avant une rechute due à la maladie. De préférence, la maladie est une maladie liée au facteur TNFα, comme par exemple la polyarthrite rhumatoïde. Cet anticorps anti-TNF peut être un anticorps monoclonal ou l'un de ses fragments, par exemple il peut s'agir d'un anticorps murin, d'un anticorps chimère, d'un anticorps humanisé ou de fragments de ceux-ci. De préférence, l'anticorps se fixe à un ou à plusieurs acides aminés du facteur TNFα humain (hTNFα) choisis dans le groupe 87-108 et 59-80. L'anticorps peut se fixer à l'épitope de A2 ou cA2. Dans la forme d'exécution préférée, l'anticorps est A2 ou cA2.
EP95917696A 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) Withdrawn EP0871641A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002218522A CA2218522A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
PCT/US1995/005155 WO1996033204A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)

Publications (2)

Publication Number Publication Date
EP0871641A1 true EP0871641A1 (fr) 1998-10-21
EP0871641A4 EP0871641A4 (fr) 2001-09-26

Family

ID=25679734

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95917696A Withdrawn EP0871641A4 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)

Country Status (4)

Country Link
EP (1) EP0871641A4 (fr)
AU (1) AU2365795A (fr)
CA (1) CA2218522A1 (fr)
WO (1) WO1996033204A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399036I1 (de) * 1989-08-07 2004-04-01 Peptide Technology Ltd Bindeligande für Tumornekrosisfaktor.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELLIOTT MICHAEL J ET AL: "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis." LANCET (NORTH AMERICAN EDITION), vol. 344, no. 8930, 1994, pages 1105-1110, XP002172700 ISSN: 0099-5355 *
ELLIOTT MICHAEL J ET AL: "Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis." LANCET (NORTH AMERICAN EDITION), vol. 344, no. 8930, 1994, pages 1125-1127, XP002172699 ISSN: 0099-5355 *
See also references of WO9633204A1 *

Also Published As

Publication number Publication date
EP0871641A4 (fr) 2001-09-26
WO1996033204A1 (fr) 1996-10-24
AU2365795A (en) 1996-11-07
CA2218522A1 (fr) 1996-10-24

Similar Documents

Publication Publication Date Title
US7227003B2 (en) Anti-TNF antibody fragments
US7160543B2 (en) Methods of inhibiting TNF-α in patients with Crohn's disease
US7204985B2 (en) Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies
US5656272A (en) Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US20070298040A1 (en) Methods of treating seronegative arthropathy with anti-TNF antibodies
EP0871641A1 (fr) Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
US20030064070A1 (en) Multiple administrations of anti-TNF antibody
US20020132307A1 (en) Anti-TNF antibodies and peptides of human tumor necrosis factor
JPH11503752A (ja) 抗ｔｎｆ抗体の複数回投与

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010814

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031126

17Q First examination report despatched

Effective date: 20031126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070220